CDKN2D, cyclin dependent kinase inhibitor 2D, 1032

N. diseases: 110; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.300 Biomarker disease CTD_human Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. 16367923 2006
CUI: C0038356
Disease: Stomach Neoplasms
Stomach Neoplasms
0.300 Biomarker group CTD_human Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. 16367923 2006
CUI: C1708349
Disease: Hereditary Diffuse Gastric Cancer
Hereditary Diffuse Gastric Cancer
0.300 Biomarker disease CTD_human Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. 16367923 2006
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment. 31616630 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Tildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri<sup>®</sup>; Ilumya™] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis. 30924030 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Tildrakizumab is a humanized IgG1 monoclonal antibody targeting interleukin-23 p19 and is approved for use in moderate to severe psoriasis. 30394141 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 GeneticVariation disease BEFREE Tildrakizumab, an inhibitor of the p19 subunit of interleukin (IL)-23, was recently Food and Drug Administration (FDA) approved for patients with moderate to severe psoriasis. 30345790 2019
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE Neurogenesis Using P19 Embryonal Carcinoma Cells. 31081818 2019
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE In this study, using Western blotting and RT-qPCR techniques and the fluorescent splicing reporters, we examined the detailed expression patterns of l- and s-afadin isoforms across various tissues and cell types, including rat organs at developmental stages, primary cultured neuronal and non-neuronal cells prepared from the developing rat brain, and in neurons in vitro generated from P19 embryonal carcinoma (EC) cells. 30572094 2019
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 AlteredExpression disease BEFREE Like BOC, SGTb is highly expressed in brain and P19 embryonal carcinoma (EC) cells differentiated into neuronal cells. 30639199 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 Biomarker group BEFREE IL-39, a heterodimer of p19 and EBI3, is a newly found cytokine and its role in the pathogenesis of neoplasia has not been studied yet. 30506430 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Since the identification of high levels of interleukin 23 (IL- 23) in psoriasis lesional skin, as well as finding that IL-23 was the most important source of the p40 subunit shared by IL-12 and IL-23, significant effort has been made in identifying potential new drugs that specifically block the unique IL-23 p19 subunit. 30215632 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets the p19 cytokine subunit in IL-23 and IL-39 and is US Food and Drug Administration (FDA) approved for the treatment of moderate-to-severe psoriasis in adult patients. 30174431 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Areas covered: We review the main adverse events associated with the biologic agents currently available for the treatment of psoriasis and the new inhibitors targeting the p19 subunit of interleukin (IL) 23 and the IL-17A receptor. 29557200 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. 29893222 2018
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Interleukin-23 (IL-23), a heterodimeric cytokine of covalently bound p19 and p40 proteins, has recently been closely associated with development of several chronic autoimmune diseases such as psoriasis, psoriatic arthritis or inflammatory bowel disease. 28100093 2017
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 Biomarker disease BEFREE Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab. 28770513 2017
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE Here, we demonstrate that BOC and ABL are induced in P19 embryonal carcinoma (EC) cells and cortical neural progenitor cells (NPCs) during neuronal differentiation. 27871935 2017
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE Murine P19 embryonal carcinoma (EC) cells are convenient to differentiate into all germ layer derivatives. 28013042 2017
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE Therefore, we examined whether allelic pairing of Oct4 loci also occurs during differentiation of F9 and P19 ECCs. 28967672 2017
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE Retinoic acid signaling has been thoroughly interrogated in ECCs, especially in the F9 and P19 murine cell models, and while we have touched on this aspect, this review purposely highlights how some key transcription factors regulate pluripotency and cell stemness prior to this signaling. 28373885 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation group BEFREE The genomic breakpoint was identified in intron 1 of CDKN2D and intron 2 of WDFY2 in patient tumor, providing direct evidence that this is a fusion gene. 24675677 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms
0.100 GeneticVariation group BEFREE We found no alterations in the CDKN2D gene; the c.90C>G (p.R30R; rs1968445) polymorphism was detected in 10% of tumors. 24022213 2013
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.100 AlteredExpression disease BEFREE Increased IL-23 p19 mRNA levels were observed for both EN-like lesions of patients with BD and skin lesions of patients with psoriasis compared with normal individuals. 18205865 2008
CUI: C0206659
Disease: Embryonal Carcinoma
Embryonal Carcinoma
0.100 Biomarker disease BEFREE The P19 EC cells differentiate to form neurons but the ability of the neurites to extend and make contacts with neighbouring neurites is compromised when treated with the hANG-ALS variants. 17916583 2008